2 active not recruiting. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Enterocolitis: new trials by email Literature Review of Enterocolitis trials Research Report on Enterocolitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations MAS825, Placebo - NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 17 | 2020-12-18 | 2026-10-09 |
| Human Milk Fortification in Extremely Preterm Infants H2MF, Bovine milk-based fortifier - Necrotizing Enterocolitis, Sepsis | Phase 2 / Phase 3 | Active not recruiting | Thomas Abrahamsson, MD, PhD | 229 | 2019-02-01 | 2024-07-23 |
Enterocolitis, Necrotizing (1) · Lymphoproliferative Syndrome, X-Linked, 2 (1) · Sepsis (1)
Digestive System Diseases (2) · Gastroenteritis (2) · Gastrointestinal Diseases (2) · Intestinal Diseases (2) · Infections (1) · Inflammation (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Systemic Inflammatory Response Syndrome (1)
Novartis Pharmaceuticals (1) · Thomas Abrahamsson, MD, PhD (1)
Czechia (1) · France (1) · Italy (1) · Japan (1) · Spain (1) · Sweden (1) · United Kingdom (1) · United States (1)
Thomas R Abrahamsson, MD, PhD (1)